ARTICLE

Synthesis and characterization of a novel functionalized azanonaborane cluster for boron neutron capture therapy

Afaf R. Genady*

Department of Chemistry, Faculty of Science, University of Tanta, 31527-Tanta, Egypt. E-mail: afafgenady@hotmail.com; Fax: +2-040-3350804; Tel: +2-040-3297974

Received 8th March 2005, Accepted 18th April 2005 First published as an Advance Article on the web 29th April 2005



The reactivity of an azanonaborane cluster containing free amino groups $\{H_2N(CH_2)_4H_2NB_8H_{11}NH(CH_2)_4NH_2\}$ towards ketones and aldehydes is investigated. In a one step reaction, the reductive amination of some ketones and aldehydes (namely acetone, benzaldehyde, 3-hydroxybenzaldehyde, 4-hydroxybenzaldehyde, 4-nitrobenzaldehyde, 4-acetoxybenzaldehyde, and 4-acetamidobenzaldehyde) with an azanonaborane cluster in the presence of $H_3BNH_2(CH_2)_4NH_2$ gives monoalkylamino derivatives of the azanonaborane cluster $\{RHN(CH_2)_4H_2NB_8$ - $H_{11}NH(CH_2)_4NHR\}$ where ($R = (Me)_2CH_-$, $C_6H_5CH_2-$, 3-OHC $_6H_4CH_2-$, 4-OHC $_6H_4CH_2-$, 4-NO₂C $_6H_4CH_2-$, 4-MeOCOC $_6H_4CH_2-$, or 4-NH $_2COC_6H_4CH_2-$). The functionalized derivatives of the $\{B_8N\}$ cluster can be used in boron neutron capture therapy for tumors (BNCT). Similarly, the reductive amination of 5-(4'-formylphenyl)-10,15,20-triphenylporphyrin with the $\{B_8N\}$ cluster gave a porphyrin bearing azanonaborane cluster, while a porphyrin dimer linked by an azanonaborane moiety was obtained following the same method, starting with a 2 : 1 molar ratio of porphyrin : $\{B_8N\}$ cluster. 5,10,15,20-Tetraformylphenylporphyrin gave the chance to increase the percentage of boron in the resulting boronated porphyrin, which is considered an important factor for a BNCT delivery agent. With these compounds, the cell toxicity using V79 cells was carried out to determine whether these compounds would have favorable biological properties.

Introduction

Boron neutron capture therapy (BNCT) is a bimodal cancer treatment based on the selective accumulation of certain ¹⁰B carriers in tumors. Subsequent irradiation with thermalized neutrons produces high linear energy transfer particles, ⁴He²⁺ (α -particle) and $^7Li^{3+}$, that cause severe damage to tumor cells through ionization processes. Azanonaborane clusters $\{(\mathbf{R}^{1}\mathbf{H}_{2}\mathbf{N})\mathbf{B}_{8}\mathbf{H}_{11}\mathbf{N}\mathbf{H}\mathbf{R}^{2}\}$ are readily prepared in good yields in easy steps from $nido-B_{10}H_{14}$, and the determination of their structures and unequivocal constitution have been reported.¹⁻³ These compounds have been shown to constitute a good entry into azacarbaborane⁴ and azametalloborane chemistry.⁵ The azanonaborane cluster also undergoes several other interesting reactions, such as: (i) a ligand-exchange reaction; (ii) N-deprotonation followed by subsequent N-alkylation; (iii) a halogenation reaction; (iv) hydrolytic decomposition to the new 5-vertex compound.⁶⁻⁸ Recently, azanonaboranes containing free hydroxy groups9 or free amino groups,10 have been used as a new class of boron clusters and considered as a promising boron moiety in BNCT. The success of BNCT depends upon the selective uptake of boron within tumor cells.¹¹ Porphyrins appear to be particularly promising tumorselective compounds because of their demonstrated tendency to accumulate in neoplastic tissue. Various boron clusters such as azanonaborane,12 polyhedral closo- and nido-carborane and closo-dodecaborate anions containing porphyrin have been synthesized and designed as BNCT agents.¹³⁻¹⁶ In order to develop the chemistry of azanonaboranes containing free amino groups such as (4-aminobutylamine)-N-aminobutyl)- $\{H_2N(CH_2)_4H_2NB_8H_{11}NH(CH_2)_4NH_2\}$ azanonaborane(11) (Fig. 1), we have become interested in the use of these compounds as starting substrates. Here we report the synthesis of new compounds containing an azanonaborane cluster by the reductive amination of some carbonyl compounds with (4-aminobutylamine)-N-aminobutyl)azanonaborane(11) $\{H_2N(CH_2)_4H_2NB_8H_{11}NH(CH_2)_4NH_2\}$ with the aim of obtaining azanonaboranes with enhanced biological significance.





Fig. 1 Structure of (4-aminobutylamine)-*N*-aminobutyl)azanonaborane(11) (*exo*-H atoms are omitted for clarity).

Results and discussion

Chemistry

The B₈N cluster is an interesting starting material for the synthesis of a wide variety of boron-containing species. The eight boron atoms offer suitable boron content derivatives and have reasonable water solubility, which makes them good candidates for the selective delivery of boron for BNCT.9,10 Functionalization of the azanonaboranes imparts a chemical reactivity which can assist their intracellular retention within tumors or provide the means to attach them to organic molecules. Azanonaborane clusters containing free amino groups $\{H_2N(CH_2)_4H_2NB_8H_{11}NH(CH_2)_4NH_2\}$ and H₃BNH₂(CH₂)₄NH₂ were prepared according to the literature.¹⁰ Addition of carbonyl compounds (1a-g) to a mixture of B₈N cluster with H₃BNH₂(CH₂)₄NH₂ in tetrahydrofuran (THF) at room temperature for 24 h (1a) or two days (1bg), followed by chromatography, resulted in the isolation of monoalkylamino derivatives of the azanonaborane cluster $\{RHN(CH_2)_4H_2NB_8H_{11}NH(CH_2)_4NHR\}$ (2a-g) in good yields (Scheme 1). Additionally, the stability of the resulting clusters is higher than the previously reported B₈N species¹⁰ at room temperature. The monitoring of the reaction mixture by NMR spectroscopy showed no evidence of the presence of



Downloaded by Duke University on 27 February 2013 Published on 29 April 2005 on http://pubs.rsc.org | doi:10.1039/B503445K H g bo H

 $H_3BNH_2(CH_2)_4NH_2 \{\delta(^{11}B) = -19.97\}$ after 24 h for compound 2a and two days for compounds 2b-g. The appearance of a new broad band $\{\delta^{(1)}B\} = -24.65\}$ was attributed to the conversion of $H_3BNH_2(CH_2)_4NH_2$ to $H_2BNH_2(CH_2)_4NHCHR$ (Scheme 1). The constitution and purity of each of the compounds (2a-g) were established by NMR, mass spectroscopy and elemental analysis. Clean ¹¹B and ¹H NMR spectra were additional criteria of purity (Table 1). The ¹¹B NMR spectroscopic data of the series of compounds 2a-g are very similar, although there are some variations in the proton shielding as the organic moiety changes (Table 1). ¹H NMR spectra of all compounds showed exchangeable singlets corresponding to the NH proton at $\delta =$ 5.8-6.2 ppm (Fig. 2). Also, ¹H and ¹³C NMR spectra indicate the appearance of new signals corresponding to the organic moiety of each carbonyl compound. Mass spectra of all compounds showed fragments corresponding to the typical pattern of boron isotopes (10 B and 11 B).

In the case of compound **2a**, the ¹H NMR spectrum showed a heptet at 2.65–2.9 ppm corresponding to one CH proton and two doublets at 1.01–1.16 ppm corresponding to six (CH₃)₂ protons (Fig. 2). Moreover the ESI-MS spectrum showed the most intense molecular ion peak (M⁺) at m/z = 355 corresponding to the ¹¹B isotope (see experimental section for details).

Computed ¹H and ¹³C NMR chemical shifts, supported by 2D-¹H ¹H cosy and 2D-¹H ¹³C cosy NMR spectra reflected the reductive amination of carbonyl compounds by the free amino groups in the B₈N clusters. Additionally the assignments of ¹³C NMR signals were based on DEPT experiments and chemical shift arguments (Fig. 3). The IR spectrum proved the absence of the free C=O group of carbonyl compounds. These observations suggested a mechanism for the formation of compounds **2a**-**g** in which the hydroborane H₃BNH₂(CH₂)₄NH₂ reduction of ketones and aldehydes most likely proceeds by an initial complexing of H₃BNH₂(CH₂)₄NH₂ with carbonyl oxygen¹⁷

Compound	$ \begin{array}{l} \mathbf{B1} \\ \boldsymbol{\delta}(^{11}\mathbf{B}) \\ [\boldsymbol{\delta}(^{1}\mathbf{H})] \end{array} $	$\begin{array}{l} \mathbf{B2} \\ \delta(^{11}\mathbf{B}) \\ [\delta(^{1}\mathbf{H})] \end{array}$	$\begin{array}{l} \mathbf{B3} \\ \delta(^{11}\mathbf{B}) \\ [\delta(^{1}\mathbf{H})] \end{array}$	$\begin{array}{l} \mathbf{B4} \\ \boldsymbol{\delta}(^{11}\mathbf{B}) \\ [\boldsymbol{\delta}(^{1}\mathbf{H})] \end{array}$	$\begin{array}{l} \mathbf{B5} \\ \delta(^{11}\mathbf{B}) \\ [\delta(^{1}\mathbf{H})] \end{array}$	$\begin{array}{l} \mathbf{B6} \\ \delta(^{11}\mathbf{B}) \\ [\delta(^{1}\mathbf{H})] \end{array}$	$\begin{array}{l} \mathbf{B7} \\ \delta(^{11}\mathbf{B}) \\ [\delta(^{1}\mathbf{H})] \end{array}$	$ \begin{array}{l} \mathbf{B8} \\ \delta(^{11}\mathbf{B}) \\ [\delta(^{1}\mathbf{H})] \end{array} $	μ H(4,5) μ H(6,7) [δ (¹ H)]	\mathbf{NH} $[\delta(^{1}\mathrm{H})]$
2a	1.62 [2.65]	-55.11 [-0.66]	-19.29 [1.18]	-34.16 [0.69]	-9.93 [2.64]	-9.93 [2.57]	-32.75 [0.69]	-31.41 [0.54]	[-2.17]	[-1.12]
2b	1.54	-54.95	-18.06	-34.31	-10.88	-10.88	-32.45	[-0.66] -30.95	[-2.021]	
•	[2.58]	[-0.71]	[1.28]	[0.78]	[2.54]	[2.47]	[0.78]	[0.53] [-0.71]	[-2.05] [-2.12]	[-1.34]
2c	1.71 [2.52]	-54.98 [-0.67]	-20.16 [1.32]	-33.95 [0.72]	-11.12 [2.56]	-11.14 [2.54]	-31.22 [0.72]	-30.67 [0.57] [-0.67]	[-2.32] [-2.29]	[-1.42]
2d	1.66 [2.51]	-55.06 [-0.65]	-20.12 [1.21]	-34.06 [0.82]	-11.24 [2.62]	-11.24 [2.57]	-32.75 [0.82]	-30.59 [0.63]	[-2.39]	[-1.56]
2e	1.72 [2.49]	-55.21 [-0.68]	-20.36 [1.28]	-34.14 [0.81]	-11.21 [2.58]	-11.21 [2.58]	-31.94 [0.81]	[-0.59] -30.06 [0.71]	[-2.39] [-2.17]	[-1.39]
2f	1.79	-55.56	-20.66	-34.16	-11.23	-11.23	-33.41	[-0.62] -30.26 [0.56]	[-2.17]	[1.52]
2g	[2.56] 1.64	[-0.67] -55.12	[1.29] -21.46	[0.86] 34.05	[2.52] 	[2.52] -10.89	[0.86] -32.36	[-0.67] -30.76	[-2.23] [-2.025]	[-1.52]
-	[2.56]	[-0.68]	[1.18]	[0.84]	[2.58]	[2.58]	[0.84]	[0.59] [-0.68]	[-2.22] [-1.99]	[-1.56]
4a	1.59 [2.49]	-54.81 [-0.59]	-19.54 [1.23]	-32.76 [0.72]	-10.16 [2.53]	-10.11 [2.53]	-31.85 [0.72]	-30.25 [0.51] [-0.59]	[-1.99] [-1.89]	[-1.29]
4b	1.76 [2.57]	-54.61 [-0.66]	-20.46 [1.19]	-33.23 [0.69]	-10.88 [2.53]	-10.89 [2.53]	-32.41 [0.69]	-30.52 [0.55] [-0.66]	[-2.14] [-2.03]	[-1.46]
6	1.61 [2.51]	-54.72 [-0.65]	-19.36 [1.18]	-33.15 [0.66]	-10.78 [2.51]	-10.78 [2.51]	-31.87 [0.68]	-30.72 [0.57] [-0.65]	[-2.11] [-2.02]	[-1.56]

Table 1 200 MHz (¹¹B, ¹H) NMR data in CDCl₃ at 20 °C for 2a-g, 4a-b and 6




Fig. 2 200 MHz¹¹B (top) and ¹¹B {¹H} (bottom) NMR spectra of compound 2a in CDCl₃ at 20 °C.




Fig. 3 200 MHz DEPT 13 C NMR spectrum of compound 2a in CDCl₃ at 20 °C.

followed by an intramolecular hydride shift and removal of H_2O to yield the required products.

Reaction of azanonaborane clusters with hydroxy acetone or isophthaloyl chloride under the same reaction conditions or at a lower temperature (0 °C) gave a white precipitate immediately. However, the monitoring of the reaction mixture by NMR spectroscopy showed that a progressive loss of the boron cluster occurred exclusively to give only boric acid. No reaction was found to occur upon treatment of the B_8N cluster with acetylacetone.


The observation that porphyrins have both selective uptake and persistence within tumors encouraged us to synthesize a series of pure compounds of porphyrins containing the B_8N cluster that may be useful in cancer treatment. We have found that the reductive amination of 5-(4'-formylphenyl)-10,15,20-triphenylporphyrin $(3a)^{18}$ with a B₈N cluster containing free amino groups in THF for two days followed by chromatography afforded both porphyrin monomer (4a) and dimer (4b) containing 9.5% and 5.6% boron by weight, respectively (Scheme 2). To achieve the incorporation of multiple azanonaborane cluster units, we started with 5,10,15,20tetraformylphenylporphyrin 5, affording boronated porphyrin bearing four azanonaborane clusters (6) in the para-position (Scheme 3). Compound 6 may be more useful as a boron carrier in BNCT than both compounds 4a and 4b, where it contains 20% boron by weight. The structures of the new compounds synthesized possess spectroscopic data in accord with the assigned structures **4a**, **4b**, and **6**. To assess the potential of these boronated porphyrins in neutron capture therapy (NCT), we will consider achieving the water solubility of these porphyrins. Insertion of trivalent metal and addition of 1N HCl may be the route to our aim.

UV–visible spectra showed that the Soret band of the boronated porphyrins are red shifted nearly 3–5 nm comparing to the nonboronated starting porphyrins.

The vibrational frequency of the B–H band ν (B–H) or the B–B band ν (B–B) was not found to be sensitive to the connection of the carbonyl compounds with free amino groups. For compounds **2a–g**, **4a–b** and **6**, ν (B–H) lies in the range of 2521–2512 cm⁻¹, while ν (B–B) varies from 1056 to 1048 cm⁻¹. Compared to the frequencies of {B₈N}¹⁰ ν (B–B) = 2529– 2541 cm⁻¹, ν (B–H) = 1065 to 1059 cm⁻¹, only slight differences were found, indicating that the intracluster bonding is not perturbed by substitution on the free amino groups.

Biology

Polyamines such as putrescine, spermidine (SPD), and spermine (SPM) are important biochemical constituents that are essential for cell growth and differentiation^{19,20} and their depletion has a growth inhibitory effect on tumors.²¹ They accumulate in the tumor cells²² and have transport systems which increase their uptake in malignant cells.23 The potential of N-benzylpolyamines as vectors of boron for tumor targeting is evidenced by a recent in vitro study.24 The in vitro toxicity test was carried out to determine whether these compounds were sufficiently nontoxic. In vitro toxicity was evaluated by exposing V79 cells (Chinese hamster fibroblasts) for 16 h to the test compounds, and comparing the number of surviving cells to the number of surviving cells not exposed to the test compounds. Cells exposed to the B₈N clusters 2b and 2e at a concentration of 0.607 mM did not survive while 2d, 2f and 6 were not toxic at this concentration, and **2a** already showed some toxicity. We conclude, in agreement with others, that the incorporation of a hydrophobic group into the chain of polyamines increases the compound's toxicity.²⁵ The survival ratio for 2c, 2f and 2g decreased when its concentrations in the medium increased from 0.607 to 3.5 mM with $LD_{50} > 1000 \ \mu$ M. The LD_{50} of SPD is 880 μ M, which is higher than the LD₅₀ of SPM, which is below $600 \ \mu M$ (Fig. 4, Table 2). According to these results, a major limitation in the use of the present compounds appears to be their cellular toxicity, especially compounds such as 2a or 2b



Scheme 3

and **2e** with hydrophobic groups. The *in vitro* toxicities of these compounds with LD_{50} values below 607 μ M were not measured at lower concentrations because the achievable concentration of boron would not be effective for BNCT.

at room temperature is advantageous over previously reported azanonaboranes. The B_8N clusters **2d**, **2f** and **6** appear not to be toxic at suitable boron concentrations. These compounds might be useful as delivery agents for BNCT.

Conclusion

In conclusion, we have succeeded in synthesizing functionalized azanonaborane clusters *via* reductive amination of some aldehydes and ketones by a one step process. New types of compounds containing both porphyrin macrocycles and polyhedral azanonaborane units in one molecule have been prepared. These compounds might be suitable for use in BNCT. As compared with azanonaboranes containing free amino groups, results reported in this study have shown that their stability

Experimental

Material and methods

The reagents, dry solvents THF and dichloromethane, were used as presented directly without further purification. All aldehydes and ketones (**1a–g**) were commercially available. 5-(4'-Formylphenyl)-10,15,20-triphenylporphyrin, 5,10,15,20-tetraformylphenylporphyrin, (4-aminobutylamine)-*N*-aminobutyl)azanonaborane(11) cluster { $H_2N(CH_2)_4H_2NB_8H_{11}NH-(CH_2)_4NH_2$ } and $H_3BNH_2(CH_2)_4NH_2$ were prepared as

 Table 2
 In vitro toxicity of B₈N clusters by V79 Cells^a

$C_{ m media}$	$C_{ m media}$			Percentage of survival (%)							
(µg of B/mL)	(mM)	2a	2b	2d	2e	2f	6				
50	0.607	<1	<1	65.15 ± 5.3	<1	59 ± 1.7	82 ± 0.87				
75	0.868			41.45 ± 3.0		35.23 ± 1.3	60.2 ± 2.68				
100	1.736			24.17 ± 3.2		18.13 ± 1.56	38.1 ± 0.85				
150	2.343			17.25 ± 1.6		10.11 ± 0.93	22.2 ± 1.28				
225	2.864			12.57 ± 1.2		7.23 ± 0.67	16.3 ± 0.45				
300	3.472			6.72 ± 1.0		4 ± 0.87	7.0 ± 0.77				

^{*a*} V79 cells were incubated with boronated compounds for 16 h at compound concentrations corresponding to the boron amounts indicated. Cells were washed (PBS), trypsinized and seeded out for colony formation. After one week, colonies were washed, stained, washed again (ethanol) and counted.




Fig. 4 Percentage (\pm SD) of the *in vitro* survival cell with respect to the concentration of the B₈N cluster compounds, SPD, and SPM. The data for SPD and SPM were taken from ref. 10.

described in the literature.^{18,10} Plate chromatography was conducted on silica gel 60 (Fluka). Elemental analyses were performed by a Perkin-Elmer 2400 automatic elemental analyzer. All compounds gave elemental analysis within $\pm 0.4\%$. UVvisible data were measured on a Varian Cary 50 bio instrument. The measurements for NMR (¹¹B, ¹H and ¹³C) were carried out on a Bruker DPX 200 spectrometer. The chemical shifts δ are given in ppm relative to $\Delta E = 100$ MHz for δ (¹H) (nominally SiMe₄), and $\Delta E = 32.083972$ MHz for δ (¹¹B) (nominally F₃BOEt₂) in CDCl₃ or CD₃CN. IR (cm⁻¹) spectra were determined as a KBr disc on a Biorad FTS-7 spectrometer. Electron spray ionization (ESI) and direct chemical ionization (DCI, reactant gas NH₃) mass spectra were recorded on a Finnigan MAT 8222. Only the most intense molecular ion peak (M^+) corresponding to the ${}^{11}B$ isotope was taken into consideration.

General procedure for the synthesis of compounds 2a–g, 4a–b, and 6

Carbonyl compound (5 mmol) was added dropwise to a solution of azanonaborane cluster (1 mmol) and $H_3BNH_2(CH_2)_4NH_2$ (2 mmol) in 30 ml dry THF at room temperature. The reaction mixture was stirred for 24 h in the case of compound **2a** and two days in the case of compounds **2b–g**, **4a–b**, and **6**. The solution was filtered off and all volatile components of the filtrate were removed under vacuum to give the desired compounds. The residue was chromatographed on silica gel using THF and CH_2Cl_2 (1 : 2) as an eluent to yield the desired product.

2a. Yield (0.5 g, 45%) as a colorless oil; $R_f = 0.3$; (found: C, 47.33; H, 12.08; N, 15.71. $B_8H_{43}C_{14}N_4$ requires C, 47.53; H, 12.16; N, 15.84%); v_{max} (KBr disc)/cm⁻¹ 3238s (NH₂/NH), 2521s (BH), 1657w (δ , NH₂/NH), 1338s (BN), 2963m, 2898m,

1472m, 1442m, 1402m, 1157m, 1115s, 745m, (δ, γ, CH₂-groups); $\delta_{\rm H}(200 \text{ MHz}; \text{CDCl}_3; \text{Me}_4\text{Si}) +6.35 (2\text{H}, \text{bs}, \text{HN}-), +3.93$ (2H, bs, H₂N-B₈), +2.82 (6H, t, -H₂CHN), +2.75 (2H, hept, -HCNH), +2.61 (2H, m, CH₂NH₂-B₈), +1.38-1.61 (8H, m, -CH₂CH₂-, -CH₂CH₂-), +1.13 (6H, d, (CH₃)₂), +1.01 (6H, d, (CH₃)₂); $\delta_{\rm C}(200 \text{ MHz}; \text{CDCl}_3; \text{Me}_4\text{Si})$ 51.76 (CH₂HNB₈), 50.54 (CH₂NH₂-B₈), 49.59, 49.17 (2C, CH₂NH), 47.2, 46.95 (2C, HNCH), 29.93, 29.14, 27.66, 26.65 (4C, -CH₂CH₂-), 23.4, 22.56 (4C, CH₃); *m/z* (ESI) 355 (M⁺, 10%).

2b. Yield: (0.58 g, 47%) as a colorless oil; $R_{\rm f} = 0.32$; (found: C, 58.95; H, 9.01; N, 12.37. $B_8H_{41}C_{22}N_4$ requires C, 59.0; H, 9.16; N, 12.51%); $v_{\rm max}$ (KBr disc)/cm⁻¹ 3239s (NH₂/NH), 2526s (BH), 1667w (δ , NH₂/NH), 1339s (BN), 2976m, 2895m, 1515m, 1467m, 1448m, 1166m, 1116s, 745m (δ , γ of CH₂groups); $\delta_{\rm H}$ (200 MHz; CD₃CN; Me₄Si) +6.35 (2H, bs, HN–), +6.5–7.12 (10H_{arom}, m, CH), +3.86 (2H, bs, H₂N–B₈), +2.78 (2H, t, -H₂CHN–B₈), +2.71 (4H, m, -H₂CNH), +2.67 (2H, m, -H₂CH₂N–B₈), +1.4–1.65 (8H, m, -CH₂CH₂–, -CH₂CH₂–); $\delta_{\rm C}$ (200 MHz; CD₃CN; Me₄Si) 130.12, 130.02, 125.2, 117.1, 115.25, 115.12, 115.08 (C_{arom}), 51.63 (CH₂HNB₈), 50.34 (H₂CH₂N–B₈), 48.98, 49.4 (2C, CH₂NH), 30.02, 29.55, 28.23, 26.95 (4C, -CH₂CH₂–); m/z (DCI) 449 (M⁺, 8%).

2c. Yield: (0.56 g, 38%) as a colorless solid; $R_{\rm f} = 0.28$; (found: C, 55.12; H, 8.05; N 11.56. $B_8H_{39}C_{22}N_4O_2$ requires C, 55.39; H, 8.16; N, 11.73%); $v_{\rm max}$ (KBr disc)/cm⁻¹ 3612s (OH), 3239s (NH₂/NH), 2522s (BH), 1661s (δ , NH₂/NH), 1336s (BN), 2973m, 2895m, 1513m, 1463m, 1446m, 1163m, 1115s, 742m (δ , γ of CH₂-groups); $\delta_{\rm H}$ (200 MHz; CD₃CN; Me₄Si) +6.35 (2H, bs, HN–), +6.97 (2H, s, OH), +6.7–7.19 (8H_{arom}, m, CH), +3.95 (2H, bs, H₂N–B₈), +2.88 (2H, t, -H₂CHN–B₈), +2.75 (4H, m, -H₂CNH), +2.71 (2H, m, -H₂CH₂N–B₈), +1.38–1.65 (8H, m, -CH₂CH₂–, -CH₂CH₂–); $\delta_{\rm C}$ (200 MHz; CD₃CN; Me₄Si) 156.8, 156.49, 130.41, 130.12, 125.83, 117.8, 115.54, 115.48, 115.43 (C_{arom}), 51.21 (CH₂HNB₈), 50.54 (H₂CH₂N–B₈), 48.98, 47.25 (2C, CH₂NH), 30.19, 29.24, 28.13, 27.25 (4C, -CH₂CH₂–); *m/z* (DCI) 479 (M⁺, 12%).

2d. Yield: (0.64 g, 43%) as a colorless oil; $R_{\rm f} = 0.31$; (found: C, 55.09; H, 8.13; N, 11.43. $B_8H_{39}C_{22}N_4O_2$ requires C, 55.39; H, 8.16; N, 11.73%); $\nu_{\rm max}$ (KBr disc)/cm⁻¹ 3605s (OH), 3238s (NH₂/NH), 2521s (BH), 1665w (δ , NH₂/NH), 1335s (BN), 2976m, 2894m, 1512m, 1458m, 1438m, 1152m, 1113s, 745m (δ , γ of CH₂-groups); $\delta_{\rm H}(200$ MHz; CD₃CN; Me₄Si) +6.35 (2H, bs, HN–), +6.95 (2H, s, OH), 6.5–7.12 (8H_{arom}, m, CH), +3.86 (2H, bs, H₂N–B₈), +2.78 (2H, t, -H₂CHN–B₈), +2.71 (4H, m, -H₂CNH), +2.67 (2H, m, -H₂CH₂N–B₈), +1.4–1.65 (8H, m, -CH₂CH₂–, -CH₂CH₂–); $\delta_{\rm C}(200$ MHz; CD₃CN; Me₄Si) 156.23, 156.2, 130.12, 130.02, 125.2, 117.1, 115.25, 115.12, 115.08 (C_{arom}), 51.45 (CH₂HNB₈), 50.35 (H₂CH₂N–B₈), 48.89, 49.51 (2C, CH₂NH), 29.56, 28.95, 27.56, 26.53 (4C, -CH₂CH₂–); m/z (ESI) = 479 (M⁺, 10%).

2e. Yield: (0.74 g, 45%) as a colorless oil; $R_f = 0.32$; (found: C, 49.12; H, 6.87; N, 15.48. $B_8H_{37}C_{22}N_6O_4$ requires C, 49.3;

1517m, 1468m, 1449m, 1167m, 1112s, 744m (δ, γ of CH₂groups); $\delta_{\rm H}(200 \text{ MHz}; \text{CD}_3\text{CN}; \text{Me}_4\text{Si}) + 6.28 (2\text{H}, \text{bs}, \text{HN}-),$ +6.5–7.18 (8H_{arom}, m, CH), +3.95 (2H, bs, H₂N–B₈), +2.88 (2H, t, -H₂CHN–B₈), +2.76 (4H, m, -H₂CNH), +2.61 (2H, m, -H₂CH₂N–B₈), +1.4–1.65 (8H, m, -CH₂CH₂-, -CH₂CH₂-); $\delta_{\rm C}(200 \text{ MHz}; \text{CD}_3\text{CN}; \text{Me}_4\text{Si})$ 155.25, 130. 12, 130.02, 125.2, 117.1, 115.25, 115.12, 115.08 (C_{arom}), 52.05 (CH₂HNB₈), 50.86 (H₂CH₂N–B₈), 48.89, 49.41 (2C, CH₂NH), 29.69, 29.58, 27.95, 26.85 (4C, -CH₂CH₂-); *m/z* (DCI) 537 (M⁺, 15%). **2f.** Yield: (0.74 g, 42%) as a colorless solid; *R*_f = 0.28; (found: C, 55.23; H, 7.38; N, 11.12. B₈H₄₃C₂₆N₄O₄, requires C, 55.57; H, 7.65; N, 11.4%); *v*_{max}(KBr disc)/cm⁻¹ 3232s (NH₂/NH), 2523s (BH), 1310s (CO), 1615w (δ, NH₂/NH), 1336s (BN), 2984m, 2892m, 1511m, 1452m, 1437m, 1156m, 1115s, 745m (δ, γ of CH₂groups); $\delta_{\rm H}(200 \text{ MHz}; \text{CD}_3\text{CN}; \text{Me}_4\text{Si}) + 6.26 (2H, bs, HN-),$ +6.56 7 12 (8H - m CH) + 4.57 (M bs, H N, B) + 2.68

7.65; N, 11.4%); ν_{max} (KBr disc)/cm⁻¹ 3232s (NH₂/NH), 2523s (BH), 1310s (CO), 1615w (δ, NH₂/NH), 1336s (BN), 2984m, 2892m, 1511m, 1452m, 1437m, 1156m, 1115s, 745m (δ, γ of CH₂-groups); δ_{H} (200 MHz; CD₃CN; Me₄Si) +6.26 (2H, bs, HN–), +6.56–7.12 (8H_{arom}, m, CH), +3.67 (2H, bs, H₂N–B₈), +2.68 (2H, t, -H₂CHNB₈), +2.65 (4H, m, -H₂CNH), +2.67 (2H, m, -H₂CH₂NB₈), 2.48 (6H, s, CH₃OCO), +1.4–1.66 (8H, m, -CH₂CH₂–, -CH₂CH₂–); δ_{C} (200 MHz; CD₃CN; Me₄Si) 186.12, 186.15 (2C, CO), 176.23, 132.11, 131.25, 126.15, 117.25, 116.23, 115.12, 115.29 (C_{arom}), 52.21 (CH₂HNB₈), 51.56 (H₂CH₂N–B₈), 49.35, 48.58 (2C, CH₂NH), 31.59, 30.15, 27.46, 27.38 (4C, -CH₂CH₂–), 26.22, 26.13 (2C, CH₃); m/z (DCI) 563 (M⁺, 10%).

H, 6.91; N, 15.68%); v_{max} (KBr disc)/cm⁻¹ 3228s (NH₂/NH),

2527 (sBH), 1597w (δ, NH₂/NH), 1332s (BN), 2978m, 2895m,

2g. Yield: (0.73 g, 45%) as a colorless oil; $R_f = 0.25$; (found: C, 53.96; H, 7.56; N, 15.65. $B_8H_{41}C_{24}N_6O_2$ requires C, 54.19; H, 7.71; N, 15.8%); v_{max} (KBr disc)/cm⁻¹ 3270s (NHCO), 3232s (NH₂/NH), 2525s (BH), 1715s (CO), 1614w (δ , NH₂/NH), 1337s (BN), 2986m, 2895m, 1515m, 1456m, 1432m, 1155m, 1115s, 745m (δ , γ of CH₂-groups); δ_H (200 MHz; CD₃CN; Me₄Si) +6.45 (2H, bs, HN–), +7.3 (2H, s, HNCO), 6.67–7.89 (8H_{arom}, m, CH), +4.01 (2H, bs, H₂N–B₈), +2.89 (2H, t, -H₂CHN–B₈), +2.76 (4H, m, H₂CNH), +2.65 (2H, m, -H₂CH₂N–B₈), +1.4–1.65 (8H, m, -CH₂CH₂–, -CH₂CH₂–); δ_C (200 MHz; CD₃CN; Me₄Si) 198.12, 198.08, (2C, HNCO), 177.89, 135.12, 133.02, 128.2, 118.1, 117.25, 116.12, 115.85 (C_{arom}), 51.98 (CH₂HNB₈), 50.58 (H₂CH₂N–B₈), 49.58, 48.47 (2C, CH₂NH), 31. 95, 30.51, 28.63, 27.87 (4C, -CH₂CH₂–); m/z (DCI) 533 (M⁺, 15%).

4a. Yield: (0.97 g, 37%) as a deep violet crystalline solid; $R_{\rm f} = 0.28$; $\lambda_{\rm max}$ (CHCl₃)/nm 420, 525, 564, 601 and 660 (10⁻³ ε /dm³ mol⁻¹cm⁻¹ 370.3, 16.8, 5.4, 5.2, and 2.6); $\delta_{\rm H}$ (200 MHz; CDCl₃; Me₄Si) -2.7 (2H, bs, HN-), +4.15 (2H, bs, H₂N-B₈), +4.2 (2H, s, CH₂), +7.05-8.25 (19H, m, H_{arom}), 8.68-8.92 (8H, m, β-pyrrole), +2.82 (2H, t, H₂CNH), +2.75 (6H, m, -H₂CNH₂), +1.4-1.62 (8H, m, -CH₂CH₂-, -CH₂CH₂-); $\delta_{\rm C}$ (200 MHz; CDCl₃; Me₄Si) 149.37, 148.82, 136.92, 135.8, 133.83, 130.82, 128.37, 125.32, 117.8, 115.03, 112.01, 108.75 (C_{porphyrin}), 51.36 (CH₂HNB₈), 50.25 (CH₂NH₂-B₈), 47.86 (C, CH₂), 49.19, 48.45 (2C, CH₂NH), 47.81, 46.19 (2C, HNCH), 30.18, 28.26, 27.13, 26.12 (4C, -CH₂CH₂-); *m/z* (ESI) = 902 (M⁺, 30%), 630 (M-B₈H₁₁NH(CH₂)₄NH₂, 100).

4b. Yield: (0.22 g, 39%) as a deep violet crystalline solid; $R_{\rm f} = 0.25$; $\lambda_{\rm max}(\rm CHCl_3)/\rm nm$ 422, 525, 562, 600, and 660 (10⁻³ $\varepsilon/\rm dm^3$ mol⁻¹cm⁻¹ 370.1, 16.8, 5.2, 5.1, and 2.6); $\delta_{\rm H}(200$ MHz; CDCl₃; Me₄Si) -2.72 (4H, bs, HN-), +4.1 (2H, bs, H₂N-B₈), +4.32 (4H, s, CH₂), +6.98-8.35 (38H, m, H_{arom}), 8.38-9.01 (16H, m, β-pyrrole), +2.92 (2H, t, H₂CNH), +2.75 (6H, m, -H₂CNH₂), +1.4-1.62 (8H, m, -CH₂CH₂-, -CH₂CH₂-); $\delta_{\rm c}(200$ MHz; CDCl₃; Me₄Si) 149.8, 148.07, 139.22, 137.2, 136.78, 135.8, 135.05, 134.62, 133.72, 131.38, 130.71, 130.32, 129.55, 128.73, 128.3, 127.32, 125.62, 117.32, 116.01, 115.6, 111.43, 108.8 (C_{porphyrin}), 51.21 (CH₂HNB₈), 50.14 (CH₂NH₂--B₈), 49.46 (2C, CH₂), 49.18, 48.42 (2C, CH₂NH), 47.63, 46.12 (2CH, HNCH), 30.19, 29.26, 28.13, 26.95 (4C, -CH₂CH₂--); m/z (ESI) 1531 (M⁺, 15%), 901 (M-630, 23), 630 (M-901, 100). 6. Yield: (0.35 g, 45%) as a deep violet crystalline solid; $R_{\rm f} = 0.21$; $\lambda_{\rm max}$ (CHCl₃)/nm 424, 526, 564, 600, and 661 (10⁻³ ϵ /dm³ mol⁻¹cm⁻¹ 369.9, 16.6, 5.1, 5.1, and 2.5); $\delta_{\rm C}$ (200 MHz; CDCl₃; Me₄Si) -2.71 (2H, bs, HN-), +4.2 (8H, bs, H₂N-B₈), +3.82 (8H, s, CH₂), +7.05-8.25 (19H, m, H_{arom}), 8.68-8.92 (8H, m, β-pyrrole), +2.84 (8H, t, H₂CNH), +2.75 (12H, m, -H₂CNH₂), +1.38-1.65 (16H, m, -CH₂CH₂-); $\delta_{\rm C}$ (200 MHz; CDCl₃; Me₄Si) 150.75, 149.28, 137.12, 136.14, 132.83, 130.82, 128.73, 126.23, 118.18, 115.03, 112.01, 108.75 (C_{porphyrin}), 51.36 (CH₂HNB₈), 50.25-48.17 (4CH₂NH₂-B₈), 53.19-51.05 (8C, CH₂NH), 48.1-42.15 (8C, HNCH), 32.15-25.16 (16C, -CH₂CH₂-); *m*/*z* (ESI) 1747 (M⁺, 21%), 1446 (M-272, 18), 630 (M-1088, 100).

Biological studies

All tests were repeated 2-3 times. For each compound, Petri dishes were seeded with V79 cells (Chinese hamster fibroblasts) in an F10 essential medium containing 5% fetal calf serum. Dishes were incubated overnight at 37 °C in a humidified atmosphere containing 5% CO2. The medium was replaced with a medium containing varying concentrations of the boron compounds (the solubility of 6 was enhanced using 1N HCl) and incubated for an additional 16 h at 37 °C. When cells were grown in SPD or SPM, 2 mM aminoguanidine was added as an inhibitor of serum amine oxidases.26 The medium was removed from the dishes. The cells were suspended by trypsinization, counted and seeded out into new dishes at different dilutions. The numbers of colonies formed after one week were compared to the numbers of colonies formed in the control without boron. The medium was removed, washed with PBS, dyed with GIEMSA for 10–15 minutes and washed again with ethanol.

Acknowledgements

The author thanks Professor Detlef Gabel, Department of Chemistry, University of Bremen, Bremen, Germany, for providing facilities for recording the NMR and mass spectra.

References

- 1 B. M. Graybill, A. R. Pitochelli and M. F. Hawthorne, *Inorg. Chem.*, 1962, 1, 626–631.
- 2 R. Lewin, P. G. Simpson and W. N. Lipscomb, J. Chem. Phys., 1963, 39, 1532–1537.
- 3 U. Dörfler, J. D. Kennedy and M. Thornton-Pett, J. Chem. Soc., Dalton Trans., 1997, 2547–2550.
- 4 U. Dörfler, D. L. Ormsby, R. Greatrex and J. D. Kennedy, *Inorg. Chim. Acta*, 2000, **304**, 268–273.
- 5 U. Dörfler, P. A. Salter, X. L. R. Fontaine, N. N. Greenwood, J. D. Kennedy and M. Thornton-Pett, *Collect. Czech. Chem. Commun.*, 1999, 64, 947–958.
- 6 U. Dörfler, C. Bauer, D. Gabel, P. N. Rath, L. Barton and D. J. Kennedy, J. Organomet. Chem., 2000, 614–615, 215–222.
- 7 C. Bauer, D. Gabel, T. D. McGrath and U. Dörfler, *Inorg. Chim. Acta*, 2002, **332**, 181–185.
- 8 C. Bauer, D. Gabel, T. Borrmann, J. D. Kennedy, C. A. Kilner, M. Thornton-Pett and U. Dörfler, J. Organomet. Chem., 2002, 657, 205– 216.
- 9 C. Bauer, U. Dörfler and D. Gabel, Eur. J. Med. Chem., 2002, 37, 649–657.
- 10 M. E. El-Zaria, U. Dörfler and D. Gabel, J. Med. Chem., 2002, 45, 5817–5817.
- 11 G. Oenbrink, P. Jürgenlimke and D. Gabel, *Photochem. Photobiol.*, 1988, 48, 451–456.
- 12 D. Gabel, C. Bauer, M. E. El-Zaria, A. R. Genady and U. Dörfler, J. Organomet. Chem., 2003, 680, 23–26.
- 13 S. B. Kahl and M.-S. Koo, J. Chem. Soc., Chem. Commun., 1990, 1769–1771.
- 14 V. I. Bregadze, I. B. Sivaev, D. Gabel and D. Wöhrle, J. Porphyrins Phthalocyanines, 2001, 5, 767–781.
- 15 R. Lauceri, R. Purrello, S. J. Shetty and M. G. H. Vicente, J. Am. Chem. Soc., 2001, 123, 5835–5836.
- 16 A. P. Phadke and A. R. Morgan, *Tetrahedron Lett.*, 1993, 34, 1725– 1728.

- 17 W. M. Jones, J. Am. Chem. Soc., 1960, 82, 2528-2532.
- 18 A. D. Pomogailo, V. F. Razumov and I. S. Voloshanovskii, J. Porphyrins Phthalocyanines, 2000, 4, 45–64.
- 19 A. E. Pegg and P. P. McCann, Am. J. Physiol.: Cell Physiol., 1982, 243, C212–C221.
- 20 C. W. Tabor and H. Tabor, Annu. Rev. Biochem., 1984, 53, 749-790.
- J. P. Moulinoux, F. Darcel, V. Quemener, R. Havouis and N. Seiler, Anticancer Res., 1991, 11, 175–180.
 Y. Li, J. L. Eisenman, D. L. Sentz, F. A. Rogers, S. S. Pan, L. T. Hu,
- 22 Y. Li, J. L. Eisenman, D. L. Sentz, F. A. Rogers, S. S. Pan, L. T. Hu, M. L. Egorin and P. S. Callery, *J. Med. Chem.*, 1996, **39**, 339–341.
- 23 N. Seiler, J. G. Delcros and J. P. Moulinoux, Int. J. Biochem. Cell Biol., 1996, 28, 843–861.
- 24 B. Martin, F. Posseme, C. Le Barbier, F. Carreaux, B. Carboni, N. Seiler, J.-P. Moulinoux and J.-G. Delcros, J. Med. Chem., 2001, 44, 3653–3664.
- 25 R. J. Bergeron, J. S. McManis, C. Z. Liu, Y. Feng, W. R. Weimar, G. R. Luchetta, Q. Wu, J. Ortiz-Ocasio, J. R. Vinson, D. Kramer and C. J. Porter, J. Med. Chem., 1994, 37, 3464–3476.
- 26 P. A. Shore and V. H. Cohn Jr., *Biochem. Pharmacol.*, 1960, 5, 91–99.